Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
Authors
Mathias Earl Palmer
Mayo Clinic, Rochester, MN;
Mathias Earl Palmer , Michael H. Storandt , Jennifer Gile , Tyler J. Zemla , Tanios S. Bekaii-Saab , Zhaohui Jin , Nguyen H. Tran , Amit Mahipal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 559)
DOI
10.1200/JCO.2023.41.4_suppl.559
Abstract #
559
Poster Bd #
D11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.
First Author: Philippe Merle
Poster
2019 Gastrointestinal Cancers Symposium
Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
First Author: Robin Kate Kelley
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.
First Author: Kazufumi Kobayashi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim